Updated on 6 August 2026
(CANCER-03) GMP manufacturing and first-in-human trial delivery for rare-cancer therapeutics
EU Grants and Funding Coordinator at Elpen Pharmaceutical Co. Inc.
Athens, Greece
About
ELPEN Pharmaceutical and its affiliated Athens LifeTech Park (Greece) offer an integrated preclinical-to-first-in-human capability for HORIZON-MISS-2027-02-CANCER-03.
ELPEN can manufacture and release the investigational oncology drug to GMP standard, supported by an emerging dedicated high-potent/cytotoxic manufacturing facility, provide formulation and drug-product development, author the manufacturing-quality (CMC) section of the regulatory/CTA submission, and act as the exploitation/commercialisation partner toward validation and market.
Via Athens LifeTech Park, the group finalises preclinical validation (in vivo and ex vivo models, rodent and swine, plus DMPK and bioanalysis), and delivers Phase 1, including first-in-human, multi-centre trials through its early-phase CRO with EU site management and registry-powered recruitment; LC-MS/MS and ligand-binding bioanalysis support safety/efficacy endpoints. Drug repurposing, explicitly in scope, fits ELPEN's develop-and-make model.
ALTP's incubator can bring qualifying start-ups/asset-owners.
Topic
- Clinical trials: HORIZON-MISS-2027-02-CANCER-03 Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
Type
- Partner seeks Consortium/Coordinator
Organisation
Similar opportunities
Project cooperation
- Clinical trials: HORIZON-HLTH-2027-02-DISEASE-14-two-stage Clinical trials for advancing innovative interventions for neurodegenerative diseases
Ilias Nikolinakos
EU Grants and Funding Coordinator at Elpen Pharmaceutical Co. Inc.
Athens, Greece
Project cooperation
(CARE-02) Pharmacovigilance and real-world patient data for personalised ADR/polypharmacy research
- Partner seeks Consortium/Coordinator
- Healthcare innovations: HORIZON-HLTH-2027-01-CARE-02 Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
Ilias Nikolinakos
EU Grants and Funding Coordinator at Elpen Pharmaceutical Co. Inc.
Athens, Greece
Project cooperation
(TOOL-01) Real-world NCD data and clinical validation for AI-biomarker development
- Partner seeks Consortium/Coordinator
- Digital health and AI: HORIZON-HLTH-2027-02-TOOL-01-two-stage Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
Ilias Nikolinakos
EU Grants and Funding Coordinator at Elpen Pharmaceutical Co. Inc.
Athens, Greece